Long-term results of combined viscotrabeculotomy-trabeculectomy in refractory developmental glaucoma.

BACKGROUND: To evaluate the outcomes of combined viscotrabeculotomy-trabeculectomy in patients with refractory developmental glaucoma and to compare the success and complication rates with classical trabeculotomy-trabeculectomy procedure. PATIENTS AND METHODS: Patients who were selected for this study had cloudy corneas with a diameter of 13 mm or greater and with an initial intraocular pressure (IOP) of 27 mmHg or more, and they were divided into two groups. Group 1 consisted of 40 eyes of 24 patients who had undergone combined viscotrabeculotomy-trabeculectomy with a mean follow-up time of 55.6+/-18.4 months, and group 2 consisted of 35 eyes of 20 patients who had undergone classical trabeculotomy-trabeculectomy with a mean follow-up time of 57.2+/-19.0 months. Pre- and postoperative IOPs, mean antiglaucoma medication, mean corneal diameter, success rates, intra- and postoperative complications were compared between two groups. RESULTS: Mean IOP reduced from a preoperative level of 33.2+/-5.3 and 32.8 mmHg to 14.2+/-3.1 and 15.3+/-3.3 in group 1 and group 2, respectively (P<0.001). The mean number of antiglaucoma medications used after surgery was significantly lower in group 1 (P<0.05). Kaplan-Meier survival analysis showed that the success probability at the last visits was 90 and 71.4% in group 1 and group 2, respectively, and the difference was statistically significant (P=0.01). The most common early postoperative complication was transient IOP elevation in group 1 and hyphema in group 2 (for each, P<0.001). CONCLUSION: Use of viscoelastic materials during trabeculotomy-trabeculectomy may increase the success rate of the procedure by prevention of postoperative hemorrhage, anterior chamber shallowing, adhesion of the incision lips or fibroblastic proliferation.

Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.

BACKGROUND: To evaluate the effectiveness of intravitreal bevacizumab injection as primary treatment of diabetic macular oedema. MATERIAL AND METHODS: Thirty eyes of 30 diabetic patients were treated with 2.5 mg of intravitreal bevacizumab injection as the primary therapy for diabetic macular oedema. The main outcome measures included best-corrected visual acuity, fundus fluorescein angiography, and macular oedema map values of Heidelberg retinal tomograph II (HRT II) before and after intravitreal injection. RESULTS: The visual acuity increased in 24 of 30 eyes (80%) during a mean follow-up time of 5.6 months. The mean baseline best-corrected LogMAR value for visual acuities of the patients before intravitreal bevacizumab injection was 1.09+/-0.23. After treatment, it was 0.90+/-0.17 at the 1-month, 0.81+/-0.24, at 3-month, and 0.77+/-0.26 at the last visit examinations and the differences were significant when compared with baseline values (for each, P<0.001). The mean oedema map values significantly decreased by 33.3% at the last visit examination when compared with preinjection values (P<0.001). Mild anterior chamber inflammation was observed in four eyes (13.3%), which resolved in a week with topical corticosteroid. No other injection- or drug-related complications were observed. CONCLUSION: Intravitreal bevacizumab application provides significant improvement in visual acuity of diabetic patients and clinical course of macular oedema, and may therefore be a promising approach in the primary treatment of diabetic macular oedema.

Long-term results of viscotrabeculotomy in congenital glaucoma: comparison to classical trabeculotomy.

BACKGROUND: To evaluate the outcomes of viscotrabeculotomy in patients with primary congenital glaucoma and to compare the success and complications rates with classical trabeculotomy. PATIENTS AND METHODS: Patients who were selected for this study had all presented with primary congenital glaucoma before the age of 12 months, and they were divided into two groups. Group 1 consisted of 58 eyes of 34 patients who underwent viscotrabeculotomy, and group 2 consisted of 51 eyes of 30 patients who underwent classical trabeculotomy. Pre-and postoperative intraocular pressures (IOPs), mean antiglaucoma medication, mean corneal diameter, success rates, intra-and postoperative complications were compared between two groups. RESULTS: Mean preoperative IOP was 30.6 (SD 5.7) mm Hg in group 1 and 29.9 (4.9) mm Hg in group 2. At the last visits, it was 16.2 (2.9) mm Hg and 17.3 (2.8) mm Hg, respectively (p<0.001). The mean number of antiglaucoma medications used after surgery was significantly lower in group 1 (p<0.05). At the last visits, the success rates of group 1 and group 2 were 91.3% and 68.6%, respectively, and the difference was statistically significant (p = 0.02). The most common early postoperative complication was transient IOP elevation in group 1 and hyphaema in group 2 (for each, p<0.001). CONCLUSION: Use of viscoelastic materials during trabeculotomy may increase the success rate of the procedure by prevention of postoperative haemorrhage, adhesion of the incision lips or fibroblastic proliferation.

Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy.

AIM: To investigate blood flow velocities in the ophthalmic and central retinal arteries (CRAs) in patients with diabetic retinopathy before and after atorvastatin treatment. METHODS: 45 patients with type 2 diabetes were included in this double-blind, placebo-controlled study. The patients with diabetes were divided into three subgroups: group 1 (n = 15) included patients with non-proliferative diabetic retinopathy (NPDR); group 2 (n = 15) had patients with proliferative diabetic retinopathy (PDR); and group 3 (n = 15; placebo group) included 8 patients with NPDR and 7 patients with PDR. The patients in groups 1 and 2 (atorvastatin group) received 10 mg atorvastatin daily for 10 weeks. Pre-treatment and post-treatment serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride were recorded before and after treatment. Ocular blood flow velocities of the ophthalmic artery and CRA were evaluated by colour Doppler imaging before and after treatment in each group. RESULTS: The baseline haemodynamic parameters were similar between atorvastatin and placebo groups (p>0.05 for both). Atorvastatin significantly decreased serum levels of total cholesterol, low-density lipoprotein cholesterol and triglycerides in groups 1 and 2 compared with pretreatment levels (p<0.001 for both). The mean peak systolic flow velocities (PSVs) of the ophthalmic artery in group 2, and the mean PSV and resistive indices of the CRA in groups 1 and 2 decreased significantly after atorvastatin treatment (p<0.05 for both), whereas the mean end diastolic flow velocity of the ophthalmic artery and CRA did not change (p>0.05). There was no significant difference in ocular blood flow velocities in the placebo group (p>0.05). CONCLUSION: Atorvastatin may have a role in reducing diabetic retinal complications, with improvement in vascular resistance and decrease in the mean PSVs of the ophthalmic artery and CRA. However, further studies with large numbers of patients are needed to obtain the long-term results of this drug.

Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion.

BACKGROUND: To evaluate the efficacy of intravitreal triamcinolone acetonide injection on persistent macular oedema in branch retinal vein occlusion that fails to respond to previous laser photocoagulation. MATERIAL AND METHODS: A total of 19 eyes of 19 patients with persistent macular oedema due to branch retinal vein occlusion were treated with 8 mg/0.2 ml of intravitreal triamcinolone acetonide injection. The main outcome measures included best-corrected visual acuity, intraocular pressure, and macular oedema map values of Heidelberg Retinal Tomograph II (HRT II) before and after intravitreal triamcinolone injection. RESULTS: The mean follow-up time was 6.2+/-1.0 months. The mean baseline best-corrected logarithm of minimal angle of resolution (LogMAR) value for visual acuities of the patients before intravitreal triamcinolone injection was 1.01+/-0.16. After treatment, it was 0.55+/-0.22 at the 1-month, 0.56+/-0.22 at 3-month, and 0.62+/-0.22 at the last visits and the differences were statistically significant when compared with baseline values (for each, P<0.001). The mean oedema map values on HRT II significantly decreased by 28.5% at 1-month, 23.8% at 3-month, and 23.8% at the last visit when compared with preinjection values (for each, P<0.001). Intraocular pressure elevation exceeding 21 mmHg was observed in 26.3% of eyes at 1-month, 15.7% at 3-month, and 5.2% at the last visit, but was controlled with topical anti-glaucomatous medications in all eyes. CONCLUSION: Intravitreal triamcinolone acetonide application is a promising approach in the treatment of persistent macular oedema due to branch retinal vein occlusion non-respondent to laser photocoagulation.

The efficacy of intravitreal triamcinolone acetonide on macular edema in branch retinal vein occlusion.

PURPOSE: To evaluate the effectiveness of intravitreal triamcinolone acetonide as primary treatment of macular edema in branch retinal vein occlusion. METHODS: Fifteen eyes of 15 patients with macular edema due to branch retinal vein occlusion (Group 1) who received 8 mg/0.2 ml of intravitreal triamcinolone injection as primary treatment were retrospectively evaluated. The control group (Group 2) consisted of 19 eyes of 19 patients who had received laser treatment for macular edema. The main outcome measures included best-corrected visual acuity, intraocular pressure, and macular edema map values of Heidelberg Retinal Tomograph II. RESULTS: In Group 1, mean visual acuity improved significantly from a mean logMAR (logarithm of minimal angle of resolution) value of 0.98+/-0.19 at baseline to a maximum of 0.24+/-0.24 during a mean follow-up time of 6.3 months. In the control group, the mean baseline log-MAR visual acuity before laser treatment was 1.02+/-0.22, and it was 0.50+/-0.28 at 6-month examinations. Mean improvement in visual acuity at 1-, 3-, and 6-month examinations was significantly higher in Group 1 when compared with the control group (for each, p<0.001). The mean edema map value of Group 1 significantly decreased by 40% at 6-month examinations when compared with preinjection value (p<0.001). In Group 1, mean increase in intraocular pressure elevation was 19.8% at the 1-month, 26.9% at 3-month, and 5.7% at 6-month visits, but intraocular pressures were under control with topical antiglaucomatous medications. CONCLUSIONS: Intravitreal triamcinolone acetonide injection may be a new and promising approach as initial therapy for macular edema due to branch retinal vein occlusion.

Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema.

PURPOSE: To evaluate the effectiveness of intravitreal triamcinolone injection on the course of diabetic macular edema. METHODS: Forty-eight eyes of 48 diabetic patients were treated with 8 mg of intravitreal triamcinolone injection as the primary therapy for diabetic macular edema. The main outcome measures included best-corrected visual acuity, fundus fluorescein angio- graphy, macular edema map values of Heidelberg Retinal Tomograph II (HRT II), and intraocular pressures before and after intravitreal injection. RESULTS: The visual acuity increased in 41 of 48 eyes (85.4%) during a mean follow-up time of 7.5 months. The mean baseline best-corrected logMAR (logarithm of minimal angle of resolution) value for visual acuities of the patients before intravitreal triamcinolone injection was 1.17+/-0.20. After treatment, it was 0.85+/-0.29 at 1 month, 0.73+/-0.30 at 3 months, and 0.74+/-0.31 at 6 months, and the differences were significant when compared with baseline values (for each, p<0.001). The mean edema map values significantly decreased by 36% at the 6-month examinations when compared with preinjection values (p<0.001). Average intraocular pressure rose 24.3%, 29.1%, and 11.8% from baseline at the 1-, 3-, and 6-month follow-up intervals. Intraocular pressure elevation exceeding 21 mmHg was observed in 8 of 48 eyes (16.6%), but was controlled with topical antiglaucomatous medications in all eyes. CONCLUSIONS: Intravitreal triamcinolone application provides significant improvement in visual acuity of diabetic patients and clinical course of macular edema, and may therefore be a promising approach in the primary treatment of diabetic macular edema.

Rieger anomaly with bilateral choroidal osteoma: coincidence or association?

PURPOSE: To report a case of Rieger anomaly associated with bilateral choroidal osteoma. CASE: An 18-year-old woman presented with corectopia, iridocorneal adhesions, and stromal hypoplasia of the iris, and was diagnosed with Rieger anomaly. RESULTS: Fundus examination revealed bilateral yellowish-orange, placoid degenerative fundus lesions with pseudopod-like edges associated with the areas of retinal pigment epithelium atrophy, indicating choroidal osteoma. Fundus fluorescein angiography showed bilateral early patchy and late diffuse hyperfluorescence. B-scan echography revealed placoid lesion at the posterior ocular coats characterized by localized areas of high ultrasound reflectivity with a corresponding retrobulbar orbital shadowing. This indicated a dense calcium foreign body. In addition, computed tomography of the orbit demonstrated bilateral plate-like thickening with calcification of the choroid that was isodense with the normal skeletal bone. CONCLUSIONS: Although Rieger anomaly is classically known as a disease of the anterior segment of the eye, choroidal osteoma may be a posterior segment finding of the disease that has not previously been reported.

Open-sky capsulorrhexis in triple procedure: with or without trypan blue?

PURPOSE: To establish the beneficial effects of trypan blue 0.1% capsule staining in open-sky capsulorrhexis during triple procedure. METHODS: Patients who underwent penetrating keratoplasty (PK) with phacoemulsification and intraocular lens (IOL) implantation were divided into two groups. Group 1 consisted of 31 eyes of 26 patients with a mean age 64.4 +/- 6.9 years and anterior lens capsule was stained with trypan blue 0.1% to perform open-sky capsulorrhexis. In Group 2, capsulorhexis was performed without staining of the anterior capsule in 19 eyes of 17 patients with a mean age 60.6 +/- 5.3 years. The rates of complete capsulorrhexis and intra- and postoperative capsule-related complications were compared between the groups. RESULTS: The most common diagnosis before PK was corneal opacification in both groups. Open-sky capsulorrhexis was not completed in 3 eyes (9.6%) in Group 1 and in 9 eyes (47.3%) in Group 2. The rates of incomplete capsulorrhexis, posterior capsule tear, and transscleral fixation IOL implantation were higher in Group 2 (for each, p < 0.05). The diameters of capsulorrhexis were smaller than 4.5 mm in one eye in Group 1 and in two eyes in Group 2, and larger than 6.5 mm in two eyes in Group 1 and in three eyes in Group 2. Malposition of IOL, zonular dialysis, retinal detachment, and pupil capture were only observed in eyes in Group 2. In the follow-up period, there were no adverse reactions due to application of trypan blue in Group 1. CONCLUSIONS: Trypan blue staining of the anterior capsule during triple procedure helps the surgeon perform open-sky capsulorrhexis more easily and safely and in proper dimensions, provides positive effects on the other steps of the surgery, and decreases the rate of posterior capsule tear formation.

Flap complications in our learning curve of laser in situ keratomileusis using the Hansatome microkeratome.

PURPOSE: To determine the incidence and the type of flap complications in our initial series of eyes undergoing laser in situ keratomileusis and the impact of microkeratome-related complications on best spectacle-corrected visual acuity. METHODS: We reviewed the charts of the 630 consecutive eyes operated in the Refractive Surgery Department of Cerrahpasa Medical School, University of Istanbul, Turkey using the Hansatome microkeratome and the Summit, SVS Apex Plus excimer laser between March 1998 and November 1999. The mean follow-up was 12.6 months. RESULTS: The incidence of total flap complications was 19.8%. Flap folds (5%) were the most common complication. The incidence of epithelial ingrowth was 3.3%. Diffuse lamellar keratitis was encountered in 20 cases (3.17%). Displaced flaps were seen shortly after the procedure in 8 eyes (1.26%) and repositioned immediately. Improper keratectomy occurred in 14 eyes (2.2%) and incomplete keratectomy in four procedures (0.63%). The presence of interface debris and hemorrhage was each 1.9%. We observed one interface abscess, which was culture-negative and cured with fortified antibiotics, and one free flap. CONCLUSIONS: Although the LASIK procedure with the Hansatome had an easy learning curve without any of the serious complications that frequently occur in this phase, we still observed flap related complications that affected visual outcome.

Long-term results of bimedial rectus recessions in infantile esotropia.

BACKGROUND: Congenital esotropia has a deviation of 50 or more prism diopters (delta). Generally, surgical alignment of the eyes is the accepted treatment but surgical techniques differ. METHODS: A total of 54 patients were evaluated. Surgery was done at a mean age of 28 months. Bimedial rectus recessions up to 8 mm were performed. RESULTS: The mean preoperative deviation was 70 delta of esotropia. Our success rate with a uniform approach was 66.6%. CONCLUSIONS: Contrary to the selective approach for large angle congenital esotropia, we do not consider initial surgery on three or more muscles. Our method is quicker, simpler, less traumatic, and leaves the lateral rectus muscles unoperated for patients requiring a second surgery.